AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira Immunologics (“Triumvira” or the “Company”), a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Teresa McRoberts as Chief Financial Officer. The Company also announced the promotion of Andreas Bader, Ph.D. to Chief Scientific Officer and Jon Irvin to Senior Vice President of Finance.
“We are pleased to welcome Teresa to our management team as we continue to advance our platform of novel T cell therapies toward the clinic. Teresa brings strong expertise in financial strategy and capital markets across the healthcare sector which will be invaluable as we enter our next phase of growth,” said Paul Lammers, M.D., M.Sc., President and CEO of Triumvira. “Both Andy and Jon have been integral to the rapid growth of Triumvira and we are also excited to announce their promotions today. Andy has played an instrumental role in shaping our scientific strategy with a track record of taking research programs from the discovery stage into the clinic, and Jon has played a critical role in guiding our financial strategy to-date as we’ve quickly scaled up our company.”
Ms. McRoberts brings more than four decades of experience in the financial sector across both the buy-side and sell-side with a focus on healthcare. Prior to joining Triumvira, she was Portfolio Manager, Senior Vice President and Senior Analyst at Alger Management, a growth-style investment management company, where she grew Alger’s Health Sciences Trust into a top 10% healthcare mutual fund. She was also previously Portfolio Manager at Morgan Stanley, Portfolio Co-Manager at Tribeca Global Management, a hedge fund owned by Citigroup, and an analyst and investment banker with J.P. Morgan. Ms. McRoberts holds a Master of Business Administration from Columbia Business School and Bachelor of Arts in English from Oberlin College.
“I am excited to join the Triumvira team as it matures into a clinical stage immunotherapy company with a broad range of T cell programs. I look forward to steering the Company’s financial and business strategy and contributing to its continued growth and success in my new role,” said Ms. McRoberts.
Dr. Bader joined Triumvira in 2018 as Senior Vice President of Research and Development. He is a seasoned biotech executive with more than 20 years of experience in oncology drug discovery and development, and business and research strategies. Previously, Dr. Bader was Co-Founder and CEO of Orros Biotherapeutics and a scientific Co-Founder of Mirna Therapeutics, where he led research programs from discovery through Phase 1 clinical trial. Prior to Mirna, Dr. Bader served as the Scientific Lead of the microRNA therapeutics program at Asuragen, Inc. Dr. Bader completed his post-doctoral training at The Scripps Research Institute and received his Ph.D. in Biochemistry and M.Sc. degree in Biology from the University of Innsbruck in Austria.
Mr. Irvin joined the Company in 2018 as Vice President of Finance. He is a seasoned financial leader with experience across publicly traded and private companies across a range of industries including biotechnology, medical, software and high technology, and public accounting. Prior to Triumvira, Mr. Irvin was the Chief Financial Officer and Vice President of Finance at Mirna Therapeutics and has served in executive financial positions at healthcare companies such as Esoterix, Topaz Technologies and BioNumerik Pharmaceuticals.
About Triumvira Immunologics
Triumvira Immunologics, Inc. (“Triumvira”) is a clinical stage immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.
Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and functions independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are in Austin, Texas, with our research facilities in Hamilton, Ontario.